Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer by Patel, Hetal et al.
                                                              
University of Dundee
Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic
in estrogen receptor- positive breast cancer
Patel, Hetal; Abduljabbar, Rezvan; Lai, Chun Fui; Periyasamy, Manikandan; Harrod, Alison;
Gemma, Carolina; Steel, Jenny; Patel, Naina; Busonero, Claudia; Jerjees, Dena; Remenyi,
Judit; Smith, Sally; Gomm, Jennifer J; Magnani, Luca; Gyorffy, Balazs; Jones, J Louise;
Fuller-Pace, Frances V; Shousha, Sami; Buluwela, Laki; Rakha, Emad A; Ellis, Ian;
Coombes, R Charles; Ali, Simak
Published in:
Clinical Cancer Research
DOI:
 10.1158/1078-0432.CCR-15-1104
Publication date:
2016
Document Version
Accepted author manuscript
Link to publication in Discovery Research Portal
Citation for published version (APA):
Patel, H., Abduljabbar, R., Lai, C. F., Periyasamy, M., Harrod, A., Gemma, C., ... Ali, S. (2016). Expression of
CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast
cancer. Clinical Cancer Research, 22(23), 5929-5938. DOI:  10.1158/1078-0432.CCR-15-1104
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
 1
Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in 
estrogen receptor positive breast cancer  
 
Hetal Patel1, Rezvan Abduljabbar2, Chun-Fui Lai1, Manikandan Periyasamy1, Alison 
Harrod1, Carolina Gemma1, Jennifer H. Steel1, Naina Patel1, Claudia Busonero1, Dena 
Jerjees2, Judit Remenyi3, Sally Smith4, Jennifer J. Gomm4, Luca Magnani1, Balázs Győrffy5, 
6, Louise J. Jones4, Frances Fuller-Pace3, Sami Shousha7, Laki Buluwela1, Emad A. Rakha2, 
Ian O. Ellis2, R. Charles Coombes1, Simak Ali1,* 
 
1Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital 
Campus, London, UK 
2Department of Cancer and Stem Cells, School of Medicine, University of Nottingham, 
Nottingham, UK 
3Division of Cancer Research, University of Dundee, Ninewells Hospital & Medical 
School, Dundee, UK 
4Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, 
John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK 
5MTA TTK Lendület Cancer Biomarker Research Group, Budapest, Hungary 
6Semmelweis University 2nd Dept. of Pediatrics, Budapest, Hungary 
7Department of Histopathology, Charing Cross Hospital, Imperial College London W6 
8RF, UK 
 
 
*Author for correspondence: Simak Ali, Department of Surgery & Cancer, Imperial 
College London, Du Cane Road, London W12 0NN, UK 
Email: simak.ali@imperial.ac.uk 
 
Running title: CDK7 expression in breast cancer 
 
 2
 
Statement of translational relevance 
Cyclin-dependent kinase 7 (CDK7) is a critical regulator of cell cycle progression and 
gene expression, processes that are frequently deregulated in cancer. As such, inhibition 
of CDK7 activity has been proposed as a therapeutic strategy for the treatment of 
cancer, an aim that is supported by the recent development of selective CDK7 inhibitors 
with potent anti-cancer activities. Since CDK7 is centrally involved in key cellular 
processes in all cells, the use of CDK7 inhibitors could be limited by a toxicity associated 
with its function in normal tissues. Using mRNA expression profiling and 
immunohistochemistry, we find that expression of CDK7, as well as the associated co-
factors CyclinH and MAT1, are all elevated in breast cancer, suggesting that this tumour 
type may be especially sensitive to CDK7 inhibition and that the CDK7 over-expression 
may allow mitigation of any toxicity seen in normal tissues.  
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ABSTRACT 
 
Purpose: CDK-activation kinase (CAK) is required for the regulation of the cell-cycle and 
is a trimeric complex consisting of Cyclin Dependent Kinase 7 (CDK7), Cyclin H and the 
accessory protein, MAT1. CDK7 also plays a critical role in regulating transcription, 
primarily by phosphorylating RNA polymerase II, as well as transcription factors such as 
estrogen receptor-α (ER). Deregulation of cell cycle and transcriptional control are 
general features of tumor cells, highlighting the potential for the use of CDK7 inhibitors 
as novel cancer therapeutics.  
 
Experimental Design: mRNA and protein expression of CDK7 and its essential co-factors 
cyclinH and MAT1, were evaluated in breast cancer samples to determine if their levels 
are altered in cancer. Immunohistochemical staining of >900 breast cancers was used to 
determine the association with clinicopathological features and patient outcome.  
 
Results: We show that expression of CDK7, cyclinH and MAT1 are all closely linked at the 
mRNA and protein level and their expression is elevated in breast cancer compared with 
the normal breast tissue. Intriguingly, CDK7 expression was inversely proportional to 
tumour grade and size and outcome analysis showed an association between CAK levels 
and better outcome. Moreover, CDK7 expression was positively associated with ER 
expression and in particular with phosphorylation of ER at serine 118, a site important 
for ER transcriptional activity.  
 
Conclusions: Expression of components of the CAK complex, CDK7, MAT1 and Cyclin H 
are elevated in breast cancer and correlates with ER. Like ERα , CDK7 expression is 
inversely proportional to poor prognostic factors and survival. 
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INTRODUCTION 
 
Cyclin dependent kinases (CDKs) control cell proliferation by regulating entry into and 
passage through the cell cycle (1). The appropriate action of cell cycle CDKs is ensured 
by regulation of their activities through the availability of partner cyclins, interaction 
with CDK inhibitors (CDKi) and through their phosphorylation. Phosphorylation at a key 
threonine residue in the activation (T) loop facilitates and/or stabilizes the CDK-cyclin 
complex (2). In metazoans, T-loop phosphorylation is mediated by the CDK-activation 
kinase (CAK), a trimeric complex consisting of CDK7, CyclinH and the accessory protein, 
MAT1. Importantly, CDK7 is also required for transcription by phosphorylating the C-
terminal heptapeptide repeat domain (CTD) of RNA Polymerase II (PolII), a step that is 
required for gene promoter release and transcription initiation by PolII. Importantly, 
CDK7 also modulates regulated gene expression by phosphorylating transcription 
factors, including p53 (3), retinoid receptors (4, 5), androgen receptor (6, 7) and ER (8). 
Ligand-dependent phosphorylation of serine 118 (Ser118), important for ERα function 
and turnover, is mediated by CDK7 (8). 
 
Deregulation of CDK activity by multiple mechanisms, for example, cyclin upregulation 
and mutation, silencing or loss of genes encoding CDK inhibitors or Rb, commonly 
feature in cancer (9, 10). Hence, the development of inhibitors of cell cycle CDKs for 
cancer treatment has received considerable attention and numerous small molecule 
inhibitors have been described (11). Surprisingly, genetic studies have indicated that cell 
cycle CDKs, with the exception of CDK1, are not essential for most cell types (12, 13). 
Nevertheless, following an initial disappointment with several candidate drugs, newer 
CDK-selective inhibitors have offered renewed optimism in the utility of these targets. In 
particular, CDK4/6 selective inhibitors have shown promise against a broad range of 
cancers, including breast cancer, but can be ineffective, for example where Rb is absent 
or inactivated (14, 15). Additionally, CDK4/6 inhibitors are efficacious in combination 
with hormone therapies, for the treatment of ERα-positive advanced breast cancer (16). 
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Transcription inhibition appears to be important for the anti-tumour activities of several 
broad range CDK inhibitors, such as flavopiridol and seliciclib, which inhibit CDK7 and 
CDK9 (phosphorylation of PolII by CDK9 is needed for transcription elongation), in 
addition to inhibiting other CDKs. The action of these drugs has been linked to a 
reduction in PolII phosphorylation and reduced expression of short-lived anti-apoptotic 
proteins such as Mcl-1 and XIAP, to promote apoptosis (15). The dual role of CDK7 in 
transcription and the cell cycle means that CDK7 inhibitors potentially provide a potent 
means of blocking cell cycle progression, together with the promotion of apoptosis by 
transcription inhibition in cell lines from a variety of cancer types, including breast, 
leukaemia, neuroblastoma and lung (17-20). In the latter tumor types, the effects of 
CDK7 on RUNX1 and MYC expression and function are critical factors in the action of 
CDK7 inhibition. A further reason for CDK7 as a cancer target is that, although required 
for early embryonic development, CDK7 was not found to be essential in adult tissues 
with low proliferative indices (21), indicating that CDK7 selective inhibitors might not 
show general toxicity in cancer patients.  
 
 
 
 We have investigated the expression of CDK7 in breast cancer, since this might further 
support the case for the use of CDK7 selective inhibitors for cancer therapy, particularly 
in this tumour type. By profiling expression of the components of the CAK complex, 
CDK7, CyclinH, and MAT1 in the normal and malignant breast, we demonstrate that 
their expression is coordinately elevated in breast cancer, especially in ER-positive 
tumours, compared with normal breast tissue. We also show that CDK7, cyclinH and 
MAT1 expression is correlated with ER levels and is related to a good patient prognosis.  
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MATERIALS AND METHODS  
 
Breast Cancer Samples 
Tumour and surrounding normal tissue: Tissue samples (snap frozen) were obtained 
from patients undergoing breast surgery between 2011 and 2013; all patients gave their 
consent according to the tissue bank protocol (see below). Samples of tumour tissue 
and surrounding morphologically normal tissue, taken >5cm from the tumour, were 
obtained from each patient.  All samples were obtained from the Barts Cancer Institute 
Breast Tissue Bank and were covered by Research Tissue Bank Ethics Approval. RNA was 
also prepared from tumours from 74 patients who presented with primary, operable 
breast cancer to the Dundee Cancer Centre between 1997 and 2012 and provided 
written, informed consent for research use of their tissues; the Tayside Tissue Bank 
under delegated authority from the Tayside Local Research Ethics Committee approved 
the use of the clinical material and data. ER immunohistochemical staining and scoring 
was carried out as described (22). TMAs were prepared from a series of primary 
operable breast cancer carcinoma cases from 1986-1999 aged 70 years or less at the 
Nottingham Breast Unit. Patient selection and treatment details have been reported 
previously (23, 24).  
 
RNA preparation and quantitative RT-PCR (qRT-PCR) 
50-100mg of frozen tissue was homogenised using TissueLyser (Qiagen, Germany) with 
stainless steel ball bearings (5mm) in 0.7 ml of lysis/binding buffer and the total RNA 
extracted using an RNeasy kit (Qiagen), according to the manufacturer’s instructions. 
RNA purity and concentration was measured using a NanodropTM 1000 
spectrophotometer (Nanodrop Technolodies, Wilmington, DE, USA). cDNA was 
prepared by reverse transcription of 2.0μg of total RNA, in a final volume of 20μl using 
RevertAid M-MuLV reverse transcriptase (Fermentas, York, UK) and random hexamer 
oligonucleotide priming. Quantitative gene expression analysis was carried out using 
real-time PCR and Taqman gene expression assays for CDK7 (Hs00361486_m1), CyclinH 
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(Hs00236923_m1), MAT1 (Hs01041574_m1) and GAPDH (Hs99999905_m1) (Life 
technologies). Gene expression was normalized to GAPDH expression using the 2-ΔΔCT 
method (25).  
 
Gene expression and correlation analysis of microarray data 
Expression of CDK7, CyclinH and MAT1 was analysed in normal breast (n=144) and 
breast cancer (n=1556) samples from the METABRIC dataset using Oncomine (26). For 
the expression of ER, CDK7, CyclinH, MAT1 and PGR in the METABRIC dataset of patient 
samples (n=1959), median expression was used as the cutoff in a Cox regression 
analysis. Kaplan-Meier survival plot, and hazard ratio with 95% confidence intervals, 
logrank p-value and correlation scores (Pearson and Spearman) were calculated and 
plotted in R using Bioconductor packages. 
 
Immunohistochemistry  
Mouse monoclonal antibodies for CDK7 (ab115181, Abcam) and cyclinH (ab54903, 
Abcam) and MAT1 (sc-135981, Santa Cruz Biotechnology) were used for 
immunohistochemistry (IHC) at a working dilution of 1:100 in Leica antibody diluent. The 
staining methodology has been described previously (24). Immunohistochemical 
detection of ER phosphorylated at serine 118 (P-Ser118) was carried out as detailed 
before (27). Immunostaining was assessed using the H-scoring method and the X-tile 
software (28) was used to produce cut-off points for low and high expression levels, as 
described (24). In brief, this involved random assignment of the patient cohort into two 
separate training and validation groups ranked by the patient follow-up time. Checking 
the obtained cut-off points to the validation set tested statistical significance. IHC and 
scoring for all other proteins has previously been described (29, 30).  
 
Statistical analyses 
Statistical analysis of IHC scores for the breast cancer TMAs was performed using SPSS 
21 software (SPSS Inc, Chicago, IL, USA). The association between CDK7, CyclinH and 
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MAT1 and clinicopathological parameters was determined using the Pearson’s chi-
squared test. Survival curves were estimated by the Kaplan-Meier method with a log-
rank test to assess the significance. Multivariate Cox proportional hazard regression 
models were used to determine independent prognostic effect of variables.   
 
siRNA transfections  
MCF-7 cells were transfected with siRNA using the lipofectamine RNAiMAX reverse 
transfection protocol (Life technologies), as described previously (31). siRNAs for CDK7 
(s2829, s2830), CyclinH (s2537 and s2538), MAT1 (s8898 and s8900) and non-targeting 
(control) siRNA (4390844) were obtained from Life Technologies, UK. Forty-eight hours 
post-transfection, cells were lysed in RIPA buffer. Immunblotting was carried out using 
antibodies for CDK7 (ab9516), CyclinH (ab54903) and ß-actin (ab6276), purchased from 
Abcam (UK), as described previously (31). Antibodies for MAT1 (sc-13598), TBP (sc-421) 
and P-Ser118 (sc-12915) were purchased from Santa Cruz (USA) and ER (VP-E614) from 
Vector laboratories. For performing RT-qPCR, MCF-7 cells were transfected with siRNAs 
for CDK7, CyclinH and MAT1, purchased from Dharmacon, USA. Total RNA was prepared 
using the RNeasy kit, according to manufacturer’s methods (Qiagen). 
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RESULTS 
 
CDK7, CyclinH and MAT1 are overexpressed in breast cancer  
 
To compare CDK7 expression in normal and malignant breast tissue, we prepared total 
RNA from 20 breast cancers and matched adjacent normal breast tissue (Fig. 1A-C, 
Supplementary Fig. 1A-C). CDK7 was detectable in all samples at the mRNA level. 
Interestingly, the majority of tumours were characterised by higher CDK7 expression, 
compared with the matched adjacent normal tissue. Mean CDK7 expression was 2.2-
fold higher in tumours, compared with the adjacent normal tissue (p=0.006). CyclinH 
and MAT1 expression was similarly elevated in breast cancer, CyclinH (p=0.0061) and 
MAT1 (p=0.0057) levels in tumours being 1.9 and 2.1 fold higher respectively, than in 
the normal breast. EpCAM is an epithelial marker, the expression of which can be 
elevated in breast cancer (32). EpCAM mRNA levels were not significantly different in 
our samples (Supplementary Fig. 1D), indicating that the elevated CDK7 expression in 
this series is unlikely to be due to lower epithelial cellularity of the adjacent normal 
tissue. IHC of a small series of breast cancer samples showed that nuclear CDK7 
immunostaining intensity was consistently higher in tumor cells, compared with CDK7 
levels in adjacent normal elements (Supplementary Fig. 1E, F). Cyclin H levels were also 
elevated in tumor cells compared with adjacent normal elements. However, MAT1 
levels were not different between normal and cancer cells.  
 
We next analysed CDK7, CyclinH and MAT1 expression in the METABRIC microarray 
dataset of 1,556 breast cancers and 144 normal breast samples (33). As observed by 
qRT-PCR in our samples, CDK7 (p = 1.49x10-38), CyclinH (p = 9.41x10-4) and MAT1 (p = 
9.06x10-10) expression was also elevated in breast cancer, compared to expression in 
normal breast in this data set (Fig. 1D).  
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Interestingly, these analyses indicated that expression of CDK7, CyclinH and MAT1 may 
be co-regulated (for example, see patient samples 1, 2, 10 and 11; Supplementary Fig. 
1A-C). Pair-wise comparison using Pearson correlation coefficient analysis showed that 
the expression of CDK7 and CyclinH is indeed strongly associated in this tumour series 
(r2=0.861; p<0.0001), as is the expression of CDK7 and MAT1 (r2=0.879; p<0.0001) and 
CyclinH and MAT1 (r2=0.862; p<0.0001) (Supplementary Fig. 2A-C). In agreement with 
this, Pearson correlation coefficient analysis of the 1,959 samples in the METABRIC 
cohort showed evidence of a relationship between expression of CDK7 and CyclinH 
(r2=0.28), CDK7 and MAT1 (r2=0.25) and an especially strong association between 
CyclinH and MAT1 expression (r2=0.69) (Supplementary Fig. 2D). The difference in 
strength of associations in our cohort and METABRIC may reflect, at least in part, 
differences in proportions of different breast cancer subtypes. Indeed, whereas 63% 
(47/74) of tumors in our cohort are ER-positive, compared with 77% (1489/1928) of the 
samples in METABRIC. Analysis of TCGA and other breast cancer data sets showed that 
mutations, amplification and/or deletion of the CDK7, cyclinH and/or MAT1 genes are 
uncommon (Supplementary Fig. 2E), so their elevated expression and/or co-regulation 
are unlikely to be the result of gene rearrangement.   
 
To determine if co-regulation of the CDK7, CyclinH and MAT1 genes can be confirmed 
experimentally in breast cancer cells, we performed siRNA for CDK7 in MCF-7 cells. 
Efficient CDK7 knockdown was achieved at both the mRNA and protein levels (Fig. 1E, 
1H). Additionally, siCDK7 transfection also resulted in CyclinH and MAT1 down-
regulation at the mRNA and protein levels (Fig. 1F-H). Similarly, transfection of MCF-7 
cells with CyclinH siRNA led to reductions in CyclinH, but also reductions in the levels of 
CDK7 and MAT1 mRNA and protein. Finally, MAT1 siRNA reduced MAT1, but also CDK7 
and CyclinH expression. By contrast, expression of the TFIIH p62 subunit was unaffected, 
as were TBP and ER levels, suggesting that the siRNA mediated lowered CAK expression 
is specific. In agreement with our findings, reduction in protein levels of all three CAK 
subunits have been reported for CDK7 and MAT1 knockout mice (21, 34). What is 
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striking from our results is that knockdown of one CAK subunit not only results in 
reduction in protein levels of the other subunits, which might be attributable to 
disruption of the CAK complex; rather mRNA levels of the other subunits are reduced, 
implicating transcriptional or post-transcriptional mechanisms in the co-ordinate 
regulation of CAK subunit mRNA levels. Finally, immunoblotting of MCF7 cells sorted by 
flow cytometry showed similar expression patterns for CDK7, cyclinH and MAT1 through 
the cell cycle, with highest levels of each subunit in G1 and G2/M (Supplementary Fig. 
3A-B). siRNA mediated knockdown of CDK7 was not associated with cell cycle arrest, but 
resulted in apoptosis (Supplementary Fig. 3C), as has been described for CDK7 inhibitors 
BS-181 and THZ1 (17, 18).    
 
 
CDK7, CyclinH and MAT1 expression is associated with better patient outcome in 
breast cancer   
 
In order to determine expression of the CAK complex proteins in breast cancer and to 
analyse associations with clinical features, we carried out IHC of breast cancer TMAs for 
CDK7 (n=945), CyclinH (n=1218) and MAT1 (n=910) (Fig. 2A). Differential staining was 
evident for different samples, so the H-scoring method and cut-off H-scores were used 
to segregate tumours into high and low expression groups. Spearman Rank correlation 
of protein levels for the CAK subunits (H-scores) showed that expression of CDK7, 
CyclinH and MAT1 is strongly associated (p<0.001; Fig. 2B), as was observed for mRNA 
levels, further evidence for an important relationship between expression of the three 
CAK subunits in breast cancer.  
 
There was a suggestion of an association of CDK7 expression with age in patients aged 
between 51-60 (p=0.042), but not with menopausal status (p=0.39) (Table 1). High 
MAT1 levels were also weakly associated with age (p=0.044), but not with menopausal 
status (p=0.22). Importantly, elevated expression of CDK7, CyclinH and MAT1 was 
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associated with markers of better prognosis. Hence, patients with high grade and larger 
tumors, or those who developed recurrent disease, featured low CDK7, CyclinH and/or 
MAT1 expression. As expected from the association of high levels of the CAK 
components with low tumor grade and reduced recurrence, high CDK7 expression was 
associated with longer breast cancer specific survival (BCSS) (log-rank = 4.11, p = 0.04) 
(Fig. 2C). Multivariate Cox hazard analysis including tumour stage, size, grade and lymph 
node (LN) status showed an increased significance of CDK7 with longer BCSS (HR=0.65 
(0.41-0.84), p=0.001) (Table 2). Multivariate analysis also showed a benefit for high 
CDK7 expression for time to distant metastasis (TTDM) (Supplementary Table 1). High 
CyclinH (log-rank = 7.32, p = 0.007) and MAT1 (log-rank = 8.43, p = 0.004) were also 
associated with longer BCSS. Univariate analysis for low or high expression of all three 
CAK subunits maintained the survival benefit (log rank = 6.09, p=0.014). In the 
multivariate analysis model tumour size, LN status and HER2 status,  along with BCSS 
were significantly associated with high CyclinH (p = 0.003) and MAT1 expression (p = 
0.016), as was high expression of all three proteins (CAK) (p=0.001) (Table 2, 
Supplementary Table 1).  
 
 
Expression levels of the CAK subunits are associated with ER expression in breast 
cancer 
 
Interestingly, CDK7 (p=0.001), CyclinH (p<0.001) and MAT1 (p<0.001) levels were higher 
in ER-positive than in ER-negative breast cancer (Table 3) and there was a positive 
association of CDK7 (p=0.002), CyclinH (p<0.001) and MAT1 (p<0.001) levels with PGR 
positivity, together indicative of higher CAK levels in luminal breast cancer. This was 
further confirmed by the fact that CDK7, cyclinH and MAT1 levels were associated with 
androgen receptor (AR) positivity, as AR expression is strongly associated with ER (35, 
36). There was also a significant association with the luminal A marker, GATA3 (37), 
although there was an inverse relationship with FOXA1, another important marker of 
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luminal A breast cancer. Indeed, CDK7, CyclinH and MAT1 levels were lower in HER2-
positive than in HER2-negative breast cancer and in triple-negative (TN), compared with 
non-TN breast cancer.  
 
Real-time RT-PCR analysis of RNAs prepared from 74 independent breast cancers 
showed that CDK7 mRNA levels are also positively associated with ER mRNA levels (r2 = 
0.56, p < 0.0001) (Supplementary Fig. 4A), as are CyclinH (r2 = 0.46, p < 0.0001) and 
MAT1 (r2 = 0.44, p < 0.0001) mRNA levels. As expected, a relationship between ER and 
PGR mRNA levels (r2 = 0.63, p < 0.0001) was also observed in this patient series. The 
association was also evident when comparing CDK7, CyclinH and MAT1 mRNA levels 
with immunohistochemically defined ER status in this sample set (supplementary Fig. 
4B, C). Further confirming this association, CDK7, CyclinH and MAT1 mRNA expression 
was also positively associated with ER mRNA levels in the METABRIC dataset 
(Supplementary Fig. 4D). Analysis of the CAK expression in the PAM50 breast cancer 
subtypes showed slightly higher expression in luminal B than in luminal A breast cancer; 
p=0.03, 0.02 and <2.2e-16 for CDK7, cyclinH and MAT1, respectively (Supplementary Fig. 
4E-G). Moreover, CAK expression was significantly higher in luminal A/B than in HER2+ 
or in basal breast cancer. Interestingly, expression of each of the CAK subunits was also 
higher in HER2-positive than in basal breast cancer.  
 
Taken together, the simplest explanation for the high expression of CAK in ER-positive 
breast cancer is that ER regulates their expression. However, treatment of MCF-7 cells 
with estrogen did not affect expression of any of the subunits (supplementary Fig. 5A). 
ER knockdown also did not alter CAK levels (supplementary Fig. 5B) and examination of 
ER ChIP-seq for MCF-7 cells (38) did not identify ER binding regions within the genes nor 
within 50 kb 5’ or 3’ to the CDK7, CyclinH or MAT1 genes, indicating that the association 
between expression of these genes and ER expression is not due to direct regulation of 
their expression by ER. Interestingly, high expression of the CAK complex in our TMA 
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series was associated with longer time to distant metastasis (TTDM) (log rank = 6.68; 
p=0.01) and BCSS in ER-positive breast cancer (log rank = 5.61; p=0.018) (Fig. 2D-E).  
 
Evidence for a role of CDK7 in phosphorylation of ER at serine 118 in breast cancer 
 
Phosphorylation of ER at serine 118 (Ser118) promotes ER activity and CDK7 has been 
shown to mediate ligand-dependent phosphorylation of Ser118 (8, 39) and CDK7 
knockdown resulted in reduction in Ser118 phosphorylation (Fig. 1H). To determine if 
Ser118 phosphorylation is related to CDK7 expression in breast cancer, we performed 
IHC for ER phosphorylated at Ser118 (P-Ser118). In agreement with previous findings 
linking Ser118 phosphorylation with better prognosis (40), Ser118 phosphorylation was 
associated with better BCSS and TTDM and BCSS, high P-Ser118 levels being correlated 
with better survival, patients with intermediate P-Ser118 have worse prognosis and 
patients with very low/absent P-Ser118 having the poorest survival (TTDM Log rank = 
19.9, p<0.001; BCSS Log rank = 13.0, p=0.005) (Supplementary Fig. 3).  
 
More than half (54.1%) of the CDK7-low breast cancers were negative or were weakly 
positive for P-Ser118, compared with just 26.2% of the CDK7-high tumours (p < 0.001; χ2 
= 56.3) (Table 4). As expected, similarly strong associations were obtained for P-Ser118 
and CyclinH (p <0.001; χ2 = 43.8), and P-Ser118 and MAT1 (p <0.001; χ2 = 66.5).  
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DISCUSSION 
 
The importance of CDK7 in cell cycle regulation and transcription has highlighted this 
kinase as a potential therapeutic target for cancer treatment. In line with this, recently 
described CDK7 selective inhibitors show anti-tumour activity in several cancer models 
(17-20). Importantly, these studies show that transcriptional drivers that are especially 
important in specific cancer types, for example, RUNX1 in leukaemia, are particularly 
sensitive to CDK7 inhibition (18). Similarly, hypersensitivity of the MYCN 
(neuroblastoma) (20) and MYC (lung cancer) (19) genes to CDK7 inhibition has been 
described and appears to be due to hypersensitivity of super-enhancers that drive 
expression of these factors. Given this diverse range of tumour types that potentially 
respond, we wanted to determine if CDK7 expression is altered in cancer, as expression 
and activity may be important factors in the utility of CDK7 inhibitors in the clinic. We 
chose to investigate CDK7 expression in breast cancer, since we have previously shown 
that a selective CDK7 inhibitor, BS-181, inhibits breast cancer cell growth in vitro and in 
vivo (17). Moreover, CDK7 directly regulates the transcriptional activity of ER by 
phosphorylating Ser118 (8, 39); thus CDK7 inhibitors might be especially effective in ER-
positive breast cancer featuring elevated Ser118 phosphorylation.  
 
Comparison of breast cancers with matched adjacent normal tissue showed that CDK7 
mRNA levels are elevated in this tumour type. This was confirmed by analysis of 
microarray datasets and is in agreement with previous reports which suggested that 
CDK7 protein levels are higher in cancer compared to the normal breast (41, 42). It is 
possible that these observations reflect differences in epithelial cell content. However, 
real-time RT-PCR for EpCAM, as well as comparison of CDK7 IHC for normal breast with 
CDK7 levels in tumor samples indicates that CDK7 levels are indeed elevated in breast 
cancer. Mutations and gene rearrangements at the CAK gene loci are uncommon, so this 
is unlikely to represent a major mechanism for high expression in breast cancer. 
Interestingly, the CDK7 and CyclinH genes are located 18 Mb apart on human 
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chromosome 5 and, are also linked in the genomes of several other vertebrates, 
including Zebrafish, chicken, rodents and man, making co-regulation through  common 
gene regulatory elements  possible.  
 
Remarkably, we observed that mRNA and protein levels of CyclinH and MAT1, both of 
which are required for CDK7 activity, are also increased in breast cancer, indicative of 
up-regulation of CAK activity in breast cancer. siRNA experiments also showed that 
knockdown of any one CAK subunit resulted in reduced expression of the other 
subunits, implying co-regulation of the expression of the CAK complex at the 
transcriptional level. Whilst the exact mechanisms underlying this co-regulation remain 
unclear, treatment with the CDK7 inhibitor BS-181 resulted in reduced CDK7 protein 
levels (17) and THZ1, a covalent CDK7 inhibitor inhibits PolII recruitment to gene 
promoters (18), indicating that expression of the CAK complex is strongly linked to CDK7 
activity. It is possible that this co-regulation is due to loss of CAK subunits in apoptotic 
cells. Notwithstanding, IHC staining of >900 breast cancers also demonstrated a 
significant association between levels of CDK7, CyclinH and MAT1, which together with 
the association for mRNA expression of the CAK subunits, provides strong evidence for 
co-regulation of CAK subunit expression in breast cancer.  
 
Interestingly, high-level expression of each of the CAK subunits was associated with 
longer survival in univariate and multivariate analyses. The relationship between CDK7 
and prognosis in breast cancer seems analogous to the relationship between ER and 
prognosis, in that ER confers a good prognosis, but is at the same time a suitable target 
for therapy. Moreover, the majority of tumours with high CDK7 levels were ER-positive, 
as were tumours with high levels of CyclinH and MAT1. In agreement with this, real-time 
RT-PCR and analysis of the METABRIC microarray datasets showed positive associations 
between mRNA levels of each CAK subunit with ER mRNA levels, as well as ER status. In 
ER-positive breast cancer, CAK expression was also associated with better prognosis. 
This does not appear to be due to higher CAK expression in luminal A compared to 
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luminal B breast cancer. Indeed, in METABRIC, CAK transcript levels are similar to, or 
higher in luminal B than in luminal A breast cancer. The mechanisms underlying the 
association between CDK7, CyclinH and MAT1 expression and ER are unclear, but it is 
interesting to note that CAK levels were strongly associated with ER phosphorylation at 
Ser118, which provides in vivo evidence for the previously described role of CDK7 in 
phosphorylating this residue (8). Ser118 phosphorylation is important not only for 
stimulating ER activity, but also regulates ER degradation and consequently ER levels 
(43, 44). This might afford a potential explanation for the relationship between levels of 
CAK and ER protein in breast cancer. Moreover, ER positively regulates its own gene 
expression, at least in part through a positive cross-regulatory loop with GATA-3 mRNA 
levels (45). CDK7 may thus promote ER gene expression by promoting its activity 
through phosphorylation of Ser118. Alternatively, transcription of the ER gene may be 
particularly sensitive to CDK7 activity, as demonstrated by the sensitivity of the RUNX1 
and MYC genes in other cancers (18).  
 
We previously reported the first specific, small molecule CDK7 inhibitor, BS-181 (17). We 
showed that BS181 promotes p53-dependent and independent apoptosis, at least in 
part by inhibiting the expression of short-lived transcripts for genes encoding inhibitors 
of apoptosis. The additional work presented here shows that CAK siRNA reduces ER 
phosphorylation, in line with its known action on ER phosphorylation at Ser118 (8). Our 
findings, therefore, offer some explanation as to why CDK7 expression carries a good 
prognosis in patients with ER positive breast cancer, in that in our sets, these patients 
have been treated with adjuvant endocrine therapy, where improved survival, is 
dependent on a functioning ER, for which Ser118 phosphorylation is critical.  
 
In summary, CDK7, CyclinH and MAT1 mRNA and protein levels are elevated in breast 
cancer, particularly in ER-positive breast cancer. Given the important role of CDK7 in 
regulation of transcription, as well as its role in the direct regulation of ER activity 
through phosphorylation of Ser118, our findings support the potential use of CDK7 
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inhibitors in the treatment of ER-positive breast cancer, either as a single agent, or in 
combination with hormonal therapy, with perhaps the most suitable group for 
treatment being ER-positive breast cancer patients with high CDK7 and P-Ser118 levels.  
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Figure legends 
 
Fig. 1. CDK7, CyclinH and MAT1 mRNA levels are elevated in breast cancer and show 
evidence of coordinate regulation. (A-C) CDK7, CyclinH and MAT1 mRNA levels, 
determined by real-time RT-PCR analysis, were normalised to the expression of GAPDH 
for RNA prepared from 20 paired tumour and adjacent normal tissues. (D) Analysis of 
microarray data from the METABRIC samples for expression of CDK7, CyclinH and MAT1 
in normal breast and breast cancer samples. (E-G) MCF-7 cells were transfected with 
two independent siRNAs for CDK7, CyclinH and MAT1. Real-time RT-PCR was performed 
using RNA prepared 48 hours after transfection. CDK7, CyclinH and MAT1 expression is 
shown relative to expression of GAPDH for three independent samples. Expression of all 
three genes was significantly reduced (p<0.001) for each siRNA when compared with 
the control siRNA. (H) Immunoblotting was performed using protein lysates prepared 
following siRNA transfection as above.  
 
Fig. 2. Immunohistochemical analysis of CDK7, CyclinH and MAT1 expression in breast 
cancer. CDK7, CyclinH and MAT1 antibodies were used to immunostain breast cancer 
TMAs. The sections were scored as CDK7 low (H-score: 0-160), CDK7 high (H-score: 161-
300), CyclinH low (H-score: 0-194), CyclinH high (H-score: 195-300), MAT1 low (H-score: 
0-179) or MAT1 high (H-score: 180-300). Negative controls were performed by omitting 
the primary antibody. (A) Staining representative of low and high H-scores is shown. (B) 
Pearson’s correlation analysis is shown, together with r2 values for each pair-wise 
comparison. (C) Kaplan-Meier plots showing breast cancer specific survival (BCSS) for 
CDK7, CyclinH and MAT1 expression in breast cancer. (D) COX regression analysis for 
time to distant metastasis (TTDM) and breast cancer specific survival (BCSS) for ER-
positive breast cancer samples only. (E) KM Plot of high versus low CAK levels in ER-
positive breast cancer.  
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Table 1. CDK7, CycH and MAT1 expression and clinic-pathological associations 
Variable  
CDK7  Expression (%) CycH  Expression  (%) MAT1  Expression  (%) 
Low High 
p-value 
Low High 
p-value 
Low High 
p-value 
(0-160) (161-300) (0-194) (195-300) (0-179) (180-300) 
Age                   
<40 16 (5.9) 65 (9.7) 
0.042 
59 (9.7) 46 (7.6) 
0.34 
38 (8.6) 40 (8.7) 
0.044 
41-50 72 (26.8) 172 (25.6) 159 (26.2) 167 (27.6) 111 (25.2) 130 (28.1) 
51-60 100 (37.2) 198 (29.5) 198 (32.6) 182 (30) 158 (35.8) 126 (27.3) 
>60 81 (30.1) 236 (30.1) 192 (31.6) 211 (34.8) 134 (30.4) 166 (35.9) 
Menopausal Status                   
Pre- 100 (37.6) 259 (38.9) 
0.39 
237 (39.4) 238 (39.5) 
0.97 
162 (37.1) 189 (41.1) 
0.22 
Post- 166 (62.4) 407 (61.1) 365 (60.6) 365 (60.5) 275 (62.9) 271 (58.9) 
Tumour Size (cm)                   
< 2.0 121 (44.8) 326 (48.9) 
0.28 
273 (45) 307 (50.6) 
0.051 
185 (42) 246 (53.7) 
<0.001 
≥ 2.0 149 (55.2) 341 (51.1) 334 (55) 300 (49.4) 255 (58) 212 (46.3) 
Grade                   
1 36 (13.4) 98 (14.7) 
0.16 
84 (13.9) 109 (18) 
<0.001 
53 (12.1) 85 (18.6) 
<0.001 2 82 (30.5) 239 (35.9) 174 (28.7) 229 (37.9) 118 (26.9) 176 (38.4) 
3 151 (56.1) 328 (49.3) 348 (57.4) 266 (44) 268 (61) 197 (43) 
Lymph Node                    
Negative 186 (68.9) 382 (57.2) 
0.001 
382 (62.9) 363 (59.8) 
0.26 
286 (65) 264 (57.5) 
0.021 
Positive 84 (31.1) 286 (42.8) 225 (37.1) 244 (40.2) 154 (35) 195 (42.5) 
Local Recurrence                   
No 210 (79.2) 555 (84.3) 
0.07 
501 (84.1) 486 (82.5) 
0.48 
355 (81.8) 376 (83.2) 
0.59 
Yes 55 (20.8) 103 (15.7) 95 (15.9) 103 (17.5) 79 (18.2) 76 (16.8) 
Regional Recurrence                   
No 212 (80) 576 (77.5) 
0.003 
510 (85.6) 516 (87.6) 
0.3 
351 (80.9) 399 (88.3) 
0.002 
Yes 53 (20) 82 (22.5) 86 (14.4) 73 (12.4) 83 (19.1) 53 (11.7) 
Distant Metastasis                   
No 149 (55.2) 417 (62.4) 
0.04 
373 (61.6) 388 (64.1) 
0.35 
251 (56.9) 304 (65.9) 
0.005 
Yes 121 (44.8) 251 (37.6) 233 (38.4) 217 (35.9) 190 (43.1) 157 (34.1) 
 
Table 2. Multivariate Cox Regression Analysis for Breast Cancer Specific 
Survival (BCSS) 
 
Variable 
 
P-value HR 95% CI 
Tumour size 0.002 1.48 1.15 1.90 
Stage <0.001 1.97 1.65 2.35 
Grade <0.001 1.78 1.45 2.19 
HER2 <0.001 1.69 1.26 2.26 
CDK7 0.001 0.65 0.51 0.84 
 
 
Variable 
 
P-value HR 95% CI 
Tumour size 0.001 1.49 1.18 1.88 
Stage <0.001 1.91 1.65 2.23 
Grade <0.001 1.85 1.54 2.23 
HER2 <0.001 1.67 1.28 2.20 
CycH 0.003 0.72 0.58 0.90 
 
  
Variable 
 
P-value HR 95% CI 
Tumour size 0.049 1.28 1.01 1.63 
Stage <0.001 1.82 1.53 2.16 
Grade 0.001 1.38 1.15 1.66 
HER2 0.001 1.66 1.24 2.23 
MAT1 0.016 0.75 0.59 095 
 
 
Variable 
 
P-value HR 95% CI 
Tumour size 0.002 1.82 1.25 2.65 
Stage <0.001 1.95 1.50 2.53 
Grade 0.10 1.29 0.95 1.76 
HER2 0.002 2.09 1.32 3.32 
CAK 0.001 0.53 0.37 0.78 
 
 
Table 3. Relationship between CDK7, Cyclin H and MAT1 expression and breast cancer subtypes       
    CDK7     Cyclin H     MAT1   
 Variable Low High p-value Low High p-value Low High p-value 
  (0-160) (161-300) (࣑2) (0-194) (195-300) (࣑2) (0-179) (180-300) (࣑2) 
ER                   
Negative 87 (32.2) 148 (22.2) 0.001 194 (32.1) 117 (19.4) <0.001 151 (34.2) 93 (20.3) <0.001 
Positive 183 (67.8) 520 (77.8) (10.4) 410 (67.9) 486 (80.6) (25.5) 291 (65.8) 365 (79.7) (21.9) 
PGR                   
Negative 128 (49.2) 248 (38.3) 0.002 292 (49.6) 191 (33) <0.001 214 (49.7) 157 (35.7) <0.001 
Positive 132 (50.8) 400 (61.7) (9.2) 297 (50.4) 388 (67) (33.1) 217 (50.3) 283 (64.3) (17.4) 
ER/PGR Status                   
ER+/PGR+ 132 (50.8) 400 (61.7) 0.003 295 (50.3) 387 (67.1) <0.001 217 (50.3) 282 (64.4) <0.001 
ER+/PGR- 46 (17.7) 108 (16.7) (11.4) 104 (17.7) 80 (13.9) (35.4) 68 (15.8) 71 (16.2) (25.6) 
ER-/PGR- 82 (31.5) 140 (21.6)   187 (31.9) 110 (19.1)   146 (33.9) 85 (19.4)   
AR                   
Negative 125 (52.7) 199 (33.2) <0.001 249 (46.5) 155 (28.9) <0.001 179 (46.9) 120 (29.3) <0.001 
Positive 112 (47.3) 400 (66.8) (27.3) 287 (53.5) 381 (71.1) (35.1) 203 (53.1) 290 (70.7) (26.0) 
FOXA1                   
Negative 67 (34.7) 209 (48.5) 0.001 154 (37.6) 199 (52.5) <0.001 119 (36.1) 150 (52.8) <0.001 
Positive (≥10) 126 (65.3) 222 (51.5) (10.3) 256 (62.4) 180 (47.5) (17.8) 211 (63.9) 134 (47.2) (17.4) 
GATA3                   
Negative/Low (<60) 154 (87.5) 277 (71.9) <0.001 310 (83.8) 229 (70.2) <0.001 245 (86) 177 (67.3) <0.001 
Positive (≥60) 22 (12.5) 108 (28.1) (16.4) 60 (16.2) 97 (29.8) (18.2) 40 (14) 86 (32.7) (26.9) 
HER2                    
Negative 212 (81.2) 566 (87.5) 0.015 506 (86.3) 500 (86.8) NS 350 (81.4) 394 (90) <0.001 
Positive 49 (18.8) 81 (12.5) (5.9) 80 (13.7) 76 (13.2)   80 (18.6) 44 (10) (13.0) 
Triple negative (TN)                   
Non-TN 207 (87.7) 554 (84.6) 0.033 453 (76.3) 523 (88.5) <0.001 329 (76.3) 390 (87.1) <0.001 
TN 56 (21.3) 101 (15.4) (4.6) 141 (23.7) 68 (11.5) (30.5) 102 (23.7) 58 (12.9) (16.9) 
 
Table 4. Phosphorylation levels of ER Serine 118 are associated with CDK7, 
CycH and MAT1 levels  
      P-Ser118-ER   
 Variable Negative Low Moderate High p-value 
  (0-50) (51-100) (101-200) (201-300) (   2) 
CDK7           
Low (0-160) 64 (43.8) 15 (10.3) 51 (34.9) 16 (11.0) <0.001 
High (161-300) 63 (15.3) 45 (10.9) 182 (44.1) 123 (29.8) (56.3) 
CycH           
Low (0-194) 81 (36.0) 31 (13.8) 74 (32.9) 39 (17.3) <0.001 
High (195-300) 68 (15.3) 47 (10.6) 197 (44.4) 132 (29.7) (43.8) 
MAT1           
Low (0-179) 84 (35.7) 30 (12.8) 97 (14.3) 24 (10.2) <0.001 
High (180-300) 38 (13.6) 27 (9.6) 109 (38.6) 106 (37.9) (66.5) 
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Variable 
BCSS 
P-value HR 95% CI 
Tumour size 0.002 2.14 1.31 3.49 
Stage <0.001 1.88 1.35 2.61 
Grade 0.03 1.50 1.03 2.18 
HER2 0.025 2.11 1.10 4.05 
CAK 0.016 0.55 0.33 0.89 
Variable 
TTDM 
P-value HR 95% CI 
Tumour size 0.007 1.81 1.18 2.79 
Stage 0.021 1.43 1.06 1.93 
Grade 0.157 1.25 0.92 1.71 
HER2 0.002 2.63 1.44 4.80 
CDK7 0.047 0.65 0.43 0.99 
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Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. 
(A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time RT-PCR analysis, are 
shown relative to expression of GAPDH for RNA prepared from 20 paired tumour and adjacent 
normal tissues. Error bars represent SEM for three technical replicates. The paired t-test was 
used to determine statistical significance of the difference in expression between adjacent 
normal tissue and paired tumour samples; p-values for differences are indicated. (D) Real-time 
RT-PCR analysis of EPCAM mRNA levels in the 20 paired tumor and adjacent normal samples. 
Real-time RT-PCR assay (Taqman assay hs00901885; Life Technologies).  (E) Representative IHC 
images for tumours that feature adjacent normal elements. (F) H-scoring of CDK7, CycH and 
MAT1 immunostaining in the adjacent normal epithelial cells and cancer cells (n=10).  
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Supplementary Figure 2. Relationship between mRNA levels of CDK7, cyclin H and MAT1 in 
breast cancer. 
(A-C) Plotted are the mean expression values for CDK7 against CyclinH, CDK7 against MAT1 and 
CyclinH versus MAT1 for each of the 20 tumours samples in Fig. 1A-C. Pearson correlation 
coefficient r2 and p-values are shown. (D) Pearson’s correlation analysis for 1,959 METABRIC 
breast cancer samples is shown in heat map form, with r2 values also shown. (E) Analysis of 
TCGA, Sanger, BCCRC and Broad Institute data sets shows that mutations, deletions and/or 
amplifications in CDK7, CyclinH and MAT1 genes is rare (<3% of cases) in breast cancer.  
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Supplementary Figure 3. Profiling of CDK7, Cyclin H and MAT1 expression in the cell cycle. 
(A) 1x106 MCF7 cells in culture treated with 10 µM EDU (Invitrogen) for 30 mins. were 
trypsinized, washed with 3ml 1% BSA and fixed with 100µl Click-iTTM fixative (component 
D) for 15 minutes. Fixed cells were washed in 3ml of 1% BSA solution and permeabilised 
with 100µl 1x saponin-based buffer (10x diluted in 1% BSA) for 15 minutes followed by 
another wash with 3ml of 1% BSA.  500µl of reaction cocktail was added to the cells for 30 
minutes. Reaction cocktail contained 438µl 1xClick-IT® reaction buffer, 10µl copper 
sulphate, 2.5µl fluorescent dye azide and 50µl reaction buffer additive per sample. Cells 
were washed in 3ml 1x saponin-based buffer and re-suspend in 500µl 1x saponin-based 
buffer. 5µl of RNAse A and 2µl of PI dye was added to each sample and mixed.  Samples 
were analysed for cell cycle profiles by BD FACS Canto (BD biosciences) and cell cycle 
phases were sorted using the BD FACS Aria IIu (BD biosciences). Cells gated as marked were 
collected for protein lysate preparation in RIPA.  
(B) Immunoblotting for cyclin A, cyclin B1, cyclin D1 and cyclin E was used to confirm the phase 
of the cell cycle of the FACS sorted MCF7 cells. Immunoblotting for CDK7, MAT1 and cyclin 
H indicates that they are expressed through the cell cycle, with highest levels in G2/M. 
Cyclin A (sc-751), cyclin B1 (sc-7393) and cyclin D1 (sc-753) antibodies, purchased from 
Santa Cruz were used at a dilution of 1:250. The Cyclin E antibody (#4129; Cell Signaling) 
was used at a dilution of 1:500.  
(C) MCF7 cells were treated with siRNAs for CDK7, cyclinH, MAT or with a control siRNA. Cells 
were used for cell cycle analysis after 48 hours, following fixation and PI labelling. 
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Supplementary Figure 4. Expression of CDK7, CyclinH and MAT1 is elevated in breast cancer. 
(A) CDK7, CyclinH, MAT1 and ER expression was determined by qRT-PCR in RNA prepared from 
74 breast cancer samples. Pearson’s correlation values for ER mRNA expression and individual 
CAK subunit mRNA expression are shown. (B) CDK7, cyclinH and MAT1 mRNA levels are plotted 
relative to GAPDH expression according to clinically defined ER status in the 74 tumour RNAs. 
(C) CAK gene expression is shownaccording to breast cancer subtypes. Expression of all three 
subunits was significantly different for ER+/PGR+ vs HER2, ER+/PGR- vs Her2+, ER+/PGR+ vs 
triple negative (TN), ER+/PGR- vs TN breast cancer (p<0.01). There was no difference in 
expression of any CAK gene between Her2+ and TN breast cancer, or between ER+/PGR+ and 
ER+/PGR- samples. (D-F) Expression analysis of METABRIC microarray data shows that 
expression of CDK7, cyclin H (CCNH) and MAT1 (MNAT1) genes is significantly higher in ER-
positive (n=1489), compared with ER-negative breast cancer (n=439) (C). There is higher 
expression of CAK genes between luminal A (n=718) and luminal B (n=488) breast cancer (D). 
Expression of CDK7, cyclin H and MAT1 is significantly higher in luminal A or luminal B breast 
cancer, compared with basal (n=329), HER2 (n=240) or ‘normal-like‘ (n=199) breast cancer (E). 
(G) Statistical significance was determined using the Mann-Whitney test.  
p-value 
CDK7 CCNH MNAT1 
ER+ vs ER- <2.2e-16 <2.2e-16 3.60E-16 
PAM50 
Luminal A vs Luminal B 0.03 0.02 <2.2e-16 
Luminal A vs Her2 2.00E-13 <2.2e-16 0.01 
Luminal B vs Her2 2.40E-15 <2.2e-16 2.70E-16 
Luminal A vs Basal <2.2e-16 <2.2e-16 2.20E-15 
Luminal B vs Basal <2.2e-16 <2.2e-16 <2.2e-16 
Her2 vs Basal 3.06E-06 0.0004 0.0006 
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Supplementary Figure 5. CDK7, CyclinH and MAT1 expression is not estrogen regulated in 
breast cancer cells. 
(A) MCF-7 cells cultured in estrogen-free culture medium (DMEM lacking phenol red and 
supplemented with 10% dextran-coated charcoal stripped fetal calf serum) were treated with 
estrogen for 16 hours, followed RNA preparation and real-time RT-PCR for CDK7, cyclinH and 
MAT1, using real-time assays described in Materials and Methods. Real-time RT-PCR assay 
(Taqman assay hs00170216; Life Technologies) was used for pS2 (TFF1) gene expression. RT-
PCR for pS2 was performed as a positive control for an ER target gene (n=3, error bars = SEM). 
(B) Immunoblotting of MCF7 cells shows that CDK7, Cyclin H and MAT1 expression is not 
affected by siRNA mediated ER knockdown. CDK7, cyclin H and MAT1 siRNAs are described in 
Materials and Methods. siER was purchased from Qiagen (catalogue no. SI03114979). 
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Supplementary Figure 6. Serine 118 phosphorylation is associated with better prognosis. 
(A) Examples of IHC staining for P-Ser118. (B) Kaplan-Meier plot showing time to distant 
metastasis for patients with absent (n=153), weak (n=80), moderate (n=307) or high (n=198) 
serine 118 phosphorylation. Log rank test (Mantel-Cox) value is shown, together with the p-
value. (C) Kaplan-Meier plot for breast cancer specific survival in patients with absent (n=149), 
weak (n=69), moderate (n=253) or high (n=160) serine 118 phosphorylation.  
Log Rank = 19.87; p<0.001 
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